Latest Biotech News

Bayer moved to expand its ophthalmology franchise, agreeing to buy Perfuse Therapeutics in a deal valuing the transaction at up to $2.4B, including up to $2.15B in milestones, according to reports...

UCB agreed to acquire Candid Therapeutics for up to $2.2B, adding the company’s clinical-stage T-cell engager and expanding UCB’s autoimmune immunology pipeline. The transaction is structured...

Madrigal Pharmaceuticals extended its metabolic dysfunction–associated steatohepatitis (MASH) expansion with additional licensing activity linked to Arrowhead Pharmaceuticals’ siRNA assets,...

Novo Nordisk reported that strong prescription performance for its oral obesity therapy boosted demand, leading the company to revise expectations upward as it released earnings and guidance...

ChromaGenix, an NC State spinout, launched a commercial platform built around synthetic peptide ligands for purifying viral vectors used in gene therapies and other biologic manufacturing. The...

Prolific Machines reported a manufacturing productivity milestone using a light-controlled, optogenetics-driven CHO platform, posting a 21 g/L titer in a 15-day intensified fed-batch run for a...

OpenBind, a UK-led initiative for AI-enabled drug discovery, released its first publicly available dataset and predictive AI model, a step meant to accelerate new target-to-lead exploration. The...

Applied BioCode announced expanded FDA 510(k) clearance for its BioCode Respiratory Pathogen Panel, adding automated extraction using Thermo Fisher Scientific’s KingFisher Flex platform. The...

Adaptive Biotechnologies raised full-year 2026 revenue guidance for its minimal residual disease (MRD) business after reporting continued momentum in Q1. The company now expects MRD revenue...

Grail reported Q1 revenue up 28% year over year, driven by growth in its Galleri multi-cancer early detection blood test. Revenue tied to Galleri reached $39.8M, and test volume increased 37% with...

UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, extending the Belgian company’s push into immune-mediated disease with next-generation T-cell engagers. The upfront consideration...

Tempus AI reported a 36% year-over-year jump in Q1 revenue to $348.1 million and raised its full-year guidance, pointing to continued demand for its AI-enabled diagnostic platform. Diagnostics...

Novo Nordisk’s Q1 results added momentum to its Wegovy pill strategy after the company adjusted its outlook around adjusted sales declines and adjusted operating profit. The update followed an...

Grail reported Q1 revenue growth of 28% year over year to $40.8 million, driven by continued expansion of its Galleri multi-cancer screening test. Galleri revenue rose 37% to $39.8 million, while...

Avalo Therapeutics’ phase 2 trial of abdakibart in hidradenitis suppurativa met the study’s primary endpoint, propelling the company toward registrational work. In a randomized trial of 253 adults...

South Korea’s MFDS approved Curocell’s Rimqarto (anbal-cel), positioning it as the first homegrown CAR T therapy in the country for advanced diffuse large B-cell lymphoma. The approval covers...

Veracyte raised full-year revenue guidance after a strong Q1, citing continued volume growth for key assays. Q1 revenue rose 21% to $139.1 million, with testing revenue increasing 26% to $135.1...

Pumpkinseed, a Stanford spinout developing silicon chip-based protein sequencing technology, raised $20 million in a Series A round to advance from peptide sequencing toward full-length protein...

CellCentric raised $220 million in a Series D financing to advance its multiple myeloma program through registration and toward potential commercialization. The transatlantic biotech said the cash...

The FDA launched and validated pilots for real-time clinical trials (RTCTs), aiming to shorten the time required for early-phase signal review by enabling endpoint and safety data reporting as...